Latest news with #HeatherMcArthur
Yahoo
20-07-2025
- General
- Yahoo
Gourock Beaver leader marks four decades of volunteering with her group
A MUCH-LOVED Gourock Beaver leader has marked four decades of service and inspiring youngsters with a special presentation from her colony. Leader of the 1 Gourock, Margaret Marrs (known as Aunty Mags), has been with the group for 40 years and her fellow leaders have called an 'inspiration' to so many youngsters over the years. A celebration for the 75-year-old was held in June where Margaret was presented with her 40-year service award as well as flowers and gifts from the group. Joe Malloy (left) and Heather MacArthur (right) presenting flowers to leader Margaret Marrs (Image: Contributed) Fellow leader Heather McArthur says Margaret is 'nothing short of a wonder' and is the kind of 'magical soul' every Scout group dreams of having led them. Heather said: 'All of the children adore her, and she has dedicated so much time to the group, so we are all so thankful for her. 'She is just like the gran of the group, and everyone looks up to her, she is the perfect role model to have. 'It's a long time for her to be volunteering so we wanted to show her how much she means to us. 'Every group needs a Margaret.' Other News PICTURES: Picnic in the park hailed huge success for Port Glasgow New Parish Church Athletes of all abilities encouraged to join Inverclyde's triathlon next month Greenock street pastor's work recognised at King's Garden Party Alongside being presented handmade cards from all 37 Beavers, District Youth Lead for Greenock and District Joe Malloy also handed over the service award to Margaret – a reminder Heather says to their Beavers that youth leadership is something to aspire to. After celebrating with her colony of beavers, the leaders and volunteers, as well as Margaret's husband Joe held an afternoon tea party filled with the leaders' favourite cakes.
Medscape
20-06-2025
- Health
- Medscape
ASCO 2025: New Standards Reshape Care in mBC
Heather McArthur, MD, describes how the 2025 ASCO Annual Meeting brought exciting advances in the metastatic breast cancer space. In PD-L1-positive triple-negative breast cancer, sacituzumab govitecan combined with pembrolizumab significantly improved progression-free survival over standard chemotherapy plus pembrolizumab, quickly becoming a new standard of care. Similarly, in HER2-positive disease, trastuzumab deruxtecan combined with pertuzumab outperformed traditional THP therapy, offering a new frontline option. Overall, these findings signify a major shift in how to treat metastatic breast cancer.
Medscape
09-06-2025
- Health
- Medscape
ASCO 2025: Key Highlights in Metastatic Breast Cancer
The 2025 ASCO Annual Meeting featured several major advances in metastatic breast cancer, which Heather McArthur, MD, reports on here. In triple-negative disease, the ASCENT-04 trial showed that combining sacituzumab govitecan with pembrolizumab significantly improved progression-free survival, suggesting a new standard for programmed death-ligand 1 (PD-L1)-positive patients. In HER2-positive disease, trastuzumab deruxtecan plus pertuzumab reduced the risk for progression or death vs the CLEOPATRA regimen in the DESTINY-Breast09 study, particularly benefiting hormone receptor-negative patients. Finally, the VERITAC-2 study showed that the oral PROTAC vepdegestrant significantly benefited patients with ESR1-mutated, estrogen receptor (ER)-positive, HER2-negative tumors, adding a promising targeted option to the treatment landscape.
Medscape
15-05-2025
- Health
- Medscape
Conference MDAngle: ASCO 2025 Metastatic Breast Cancer
Preconference Considerations ASCO 2025: Previewing Updates in Metastatic Breast Cancer Dr McArthur is eager to attend the 2025 ASCO Annual Meeting, where key breast cancer studies will be presented. Highlights include DESTINY-Breast09 and ASCENT-04, showing promising results for antibody-drug conjugates in HER2-positive and triple-negative breast cancer. Additionally, EMBER-3, INAVO120, and VERITAC-2 offer new insights into targeted therapies for HR-positive disease. Dr McArthur sees these findings as advancing precision medicine. Quick Clinical Takeaways Coming soon: Dr McArthur highlights new data and progress regarding metastatic breast cancer immediately following ASCO. How Will My Patients Benefit? Coming soon: Reflections from Dr McArthur on how new data from ASCO will affect her patients with metastatic breast cancer. Image 1: Heather McArthur, MD, MPH
Medscape
15-05-2025
- Health
- Medscape
ASCO 2025: Previewing Updates in Metastatic Breast Cancer
Heather McArthur, MD, looks forward to ASCO 2025, where several pivotal studies in breast cancer will be presented. Key highlights include the DESTINY-Breast09 trial, which showed a significant improvement in progression-free survival with the combination of trastuzumab deruxtecan and pertuzumab in HER2-positive advanced breast cancer. Another major focus is the ASCENT-04 trial, demonstrating benefits of sacituzumab govitecan plus pembrolizumab in PD-L1-positive metastatic triple-negative breast cancer. In HR-positive disease, attention will be on the EMBER-3, INAVO120, and VERITAC-2 studies, each offering insights into novel targeted and endocrine therapies. Dr McArthur notes that these findings mark continued momentum in the antibody-drug conjugate and precision medicine landscapes.
